Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (VVOS) Stock Overview
Explore Vivos Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
39.3M
P/E Ratio
-5.01
EPS (TTM)
$-1.04
ROE
-1.70%
VVOS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Vivos Therapeutics, Inc. (VVOS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 89.69, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.08.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.01 and a market capitalization of 39.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
R. Kirk Huntsman
109
9137 Ridgeline Boulevard, Highlands Ranch, CO
2020